01—Abstract
Summary
Summary of the 10-Q filed August 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated reported a quarterly report for the period ended June 30, 2024, showing product revenues, net of $90.3 milliona for the three months ended June 30, 2024, up 17.0% from $77.2 million, driven by growth in ARIKAYCE sales in the US, Japan, and Europe and the rest of the world.
Net loss was $300.6 millionb for the quarter and $457.7 million for the six months ended June 30, 2024. Operating expenses included R&D of $146.7 million and SG&A of $106.6 million in the quarter, and the quarterly change in fair value of deferred and contingent consideration liabilities was a $103.7 million charge, which the filing attributes primarily to the increase in the company's share price. The balance sheet strengthened significantly during the period.
Cash and cash equivalents rose to $1,246.8 millionc as of June 30, 2024, from $482.4 million at December 31, 2023, reflecting net proceeds of $713.2 million from a May 2024 common stock offering at $51.50 per share and the maturity of $300.0 million of marketable securities. Shareholders' equity turned positive at $38.8 million, compared with a deficit of $331.9 million at year-end 2023. The company states it has sufficient funds for at least the next 12 months, while noting that future cash requirements are expected to be substantial.
Clinically, the company reported positive topline results from the Phase 3 ASPEN trial of brensocatib in May 2024, with both doses showing statistically significant reductions in the annualized rate of pulmonary exacerbations versus placebo (21.1% for 10 mg and 19.4% for 25 mg). It plans to file a new drug application with the FDA in the fourth quarter of 2024. The company also called its 1.75% 2025 Convertible Notes for redemption on August 9, 2024, and as of August 7, 2024, holders of $224.7 milliond of those notes had elected to convert.
02—Key points
Key Highlights
- Product revenues, net rose 17.0% to $90.3 million in Q2 2024 and 16.4% to $165.8 million for the six months, driven by ARIKAYCE sales growth.
- Net loss was $300.6 million for Q2 2024 and $457.7 million for the six months ended June 30, 2024, including a $103.7 million quarterly charge for the change in fair value of deferred and contingent consideration, primarily due to the increase in share price.
- Cash and cash equivalents increased to $1,246.8 million at June 30, 2024, from $482.4 million at December 31, 2023, after $713.2 million in net proceeds from a May 2024 equity offering.
- Shareholders' equity was $38.8 million at June 30, 2024, compared with a deficit of $331.9 million at December 31, 2023.
- Positive ASPEN Phase 3 topline results for brensocatib were announced in May 2024; an NDA filing is planned for the fourth quarter of 2024.
- The company called its 2025 Convertible Notes for redemption on August 9, 2024, and $224.7 million of those notes had been elected for conversion as of August 7, 2024.
- The 2028 Convertible Notes became convertible by holders on July 1, 2024, after the stock price trigger was satisfied.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 8, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $90.34M$77.23M | +17.0% |
| Cost of Revenue | $20.96M$16.59M | +26.3% |
| Gross Profit | $69.38M$60.63M | +14.4% |
| R&D Expenses | $146.75M$196.97M | −25.5% |
| SG&A Expenses | $106.57M— | — |
| Operating Expenses | $379.24M$312.76M | +21.3% |
| Operating Income | -$288.90M-$235.53M | −22.7% |
| Interest Expense | $21.27M$20.62M | +3.1% |
| Net Income | -$300.61M-$244.81M | −22.8% |
| EPS (Basic) | $-1.94$-1.78 | −9.0% |
| EPS (Diluted) | $-1.94$-1.78 | −9.0% |
| Shares Outstanding (Basic) | 154.70M137.55M | +12.5% |
| Shares Outstanding (Diluted) | 154.70M137.55M | +12.5% |
05—Questions
Frequently Asked Questions
How much did Insmed's ARIKAYCE revenue grow in the second quarter of 2024?
Product revenues, net were $90.3 million for the three months ended June 30, 2024, compared with $77.2 million in the same period of 2023, an increase of 17.0%. US revenues were $63.8 million, Japan $21.1 million, and Europe and rest of world $5.4 million.
Why was the net loss so large this quarter?
The net loss was $300.6 million for the quarter. The filing attributes a $103.7 million change in fair value of deferred and contingent consideration liabilities, primarily due to the increase in the company's share price, along with R&D expenses of $146.7 million, SG&A expenses of $106.6 million, and interest expense of $21.3 million.
Does Insmed have enough cash to fund operations?
The company had $1,246.8 million in cash and cash equivalents at June 30, 2024. It states that it currently has sufficient funds to meet its financial needs for at least the next 12 months, but that its future cash requirements are expected to be substantial and it may raise additional capital.
What is the status of brensocatib?
Positive topline results from the Phase 3 ASPEN trial were announced in May 2024, with both doses meeting the primary endpoint of reducing the annualized rate of pulmonary exacerbations versus placebo (21.1% for 10 mg and 19.4% for 25 mg). The company plans to file a new drug application with the FDA in the fourth quarter of 2024. AstraZeneca's option to further develop brensocatib in COPD or asthma expired in June 2024 without an agreement.
What changes occurred in the company's debt during the period?
The 1.75% 2025 Convertible Notes were called for redemption on August 9, 2024, and as of August 7, 2024, holders of $224.7 million of principal had elected to convert into 5,739,433 shares of common stock. The $350 million Term Loan and the $150 million Royalty Financing Agreement remain outstanding, and the 2028 Convertible Notes became convertible by holders on July 1, 2024.
06—Continue